1. How to provide the needed protection from COVID-19 to patients with hematologic malignancies
- Author
-
Ribas, Antoni, Dhodapkar, Madhav V, Campbell, Katie M, Davies, Faith E, Gore, Steven D, Levy, Ronald, and Greenberger, Lee M
- Subjects
Prevention ,Immunization ,Cancer ,Vaccine Related ,Emerging Infectious Diseases ,Patient Safety ,Hematology ,Good Health and Well Being ,Adult ,COVID-19 ,COVID-19 Vaccines ,Hematologic Neoplasms ,Humans ,Immunization ,Secondary ,SARS-CoV-2 - Abstract
Patients with hematologic malignancies are particularly vulnerable to COVID-19 infections, and upon a pooled data analysis of 24 publications, there is evidence that they have suboptimal antibody responses to COVID-19 vaccination and boosters. To provide them the needed additional protection from COVID-19, it is imperative to achieve a 100% full immunization rate in health care workers and adult caretakers, and to foster research to test higher doses and repeated rounds of COVID-19 vaccines and the use of passive immune prophylaxis and therapy.
- Published
- 2021